| The development of proteasome inhibitors as anticancer drugs. | |
| | |
MedLine Citation:
|
PMID: 15144949 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins. Because these pathways are critical for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy. Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clinical trials. Efficacy and safety results from a phase 2 clinical trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy. |
| | |
Authors:
|
Julian Adams |
Related Documents
:
|
20082139 - E1a oncogene expression inhibits pthrp p3 promoter activity and sensitizes human prosta... 17291459 - Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cel... 19325839 - Prodrugs of fluoro-substituted benzoates of egc as tumor cellular proteasome inhibitors... 12752669 - Regulation of apoptosis by ubiquitination. 9713489 - Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to... 19034669 - Calpain and proteasomal regulation of antiretroviral zinc finger protein otk18 in human... 21890409 - 'necrosome'-induced inflammation: must cells die for it? 21285529 - Autophagy and apoptosis are redundantly required for c. elegans embryogenesis. 19789309 - Dendritic cell vaccination combined with ctla4 blockade in patients with metastatic mel... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cancer cell Volume: 5 ISSN: 1535-6108 ISO Abbreviation: Cancer Cell Publication Date: 2004 May |
Date Detail:
|
Created Date: 2004-05-17 Completed Date: 2004-06-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101130617 Medline TA: Cancer Cell Country: United States |
Other Details:
|
Languages: eng Pagination: 417-21 Citation Subset: IM |
Affiliation:
|
Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA. julian.adams@ipi.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Boronic Acids / therapeutic use* Clinical Trials as Topic Humans Multiple Myeloma / drug therapy* Protease Inhibitors / therapeutic use* Pyrazines / therapeutic use* Ubiquitins / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/Ubiquitins; 0/bortezomib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Next Document: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, fr...